News
NGNE
35.25
-3.56%
-1.30
Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029
TipRanks · 3h ago
Neurogene reports Q2 EPS ($1.53), consensus ($1.38)
TipRanks · 5h ago
Neurogene GAAP EPS of -$1.05 beats by $0.37
Seeking Alpha · 5h ago
Weekly Report: what happened at NGNE last week (0803-0807)?
Weekly Report · 1d ago
Neurogene's Gene Therapy Data May Finally Give the Market Something to Price In
Barchart · 4d ago
Weekly Report: what happened at NGNE last week (0727-0731)?
Weekly Report · 08/03 09:01
Weekly Report: what happened at NGNE last week (0720-0724)?
Weekly Report · 07/27 09:01
Weekly Report: what happened at NGNE last week (0713-0717)?
Weekly Report · 07/20 09:01
Weekly Report: what happened at NGNE last week (0706-0710)?
Weekly Report · 07/13 09:01
Neurogene (NGNE) Receives a Buy from LifeSci Capital
TipRanks · 07/11 14:35
Short Report: Ondas bearish bets at record highs
TipRanks · 07/11 02:00
Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design
TipRanks · 07/07 15:45
Weekly Report: what happened at NGNE last week (0629-0703)?
Weekly Report · 07/06 09:01
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data
Seeking Alpha · 07/02 18:33
Neurogene bolsters cash runway with equity offering
TipRanks · 07/02 10:28
Neurogene prices $125M equity offering
Seeking Alpha · 07/01 11:19
Neurogene prices 3.5M shares at $30.00 in public offering
TipRanks · 07/01 11:11
Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants
Benzinga · 07/01 11:04
Neurogene 75M Spot Secondary; re-offered at $30.00
TipRanks · 06/30 22:35
Neurogene to Sell Shares in Secondary Offering
Dow Jones · 06/30 20:52
More
Webull provides a variety of real-time NGNE stock news. You can receive the latest news about Neurogene through multiple platforms. This information may help you make smarter investment decisions.
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.